New drug for anemia from kidney disease on dialysis
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called BCD-131 (a biosimilar to Mircera) for treating anemia in people with kidney disease on dialysis. It compares the new drug to the standard treatment to see if it works just as well and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have end-stage kidney disease and be on dialysis (hemodialysis or peritoneal dialysis) for at least 90 days.
- You must have been using a steady dose of a medicine called erythropoietin (like Epogen, Procrit, or Aranesp) for at least 90 days.
- Your hemoglobin level must be between 100 and 120 g/L (about 10 to 12 g/dL).
- Your iron, vitamin B12, and folic acid levels must be normal.
- You cannot have other causes of anemia, recent blood transfusions, active infections, certain heart conditions, or a history of blood clots in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, pegmolesatide, to treat anemia in people who have been on dialysis for at least three months. It aims to help improve red blood cell levels without needing as many other anemia treatments.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
This trial tests a new oral medication (QLG1218, also called daprodustat) to treat anemia in people with chronic kidney disease who are on hemodialysis. It is comparing the new drug to the usual injected ESA medicines to see if it works as well or better.
This trial tests two different doses of pegmolesatide to treat anemia in people with chronic kidney disease who are not on dialysis. It aims to find which dose works better to raise red blood cell levels.
Hear when a new Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.